Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
AND019
i
Other names:
AND019
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Hangzhou Andao Pharma
Drug class:
Selective estrogen receptor degrader
Related drugs:
‹
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
imlunestrant (7)
AZD9833 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
imlunestrant (7)
AZD9833 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (NCT05187832)
Phase 1
Kind Pharmaceuticals LLC
Kind Pharmaceuticals LLC
Recruiting
Phase 1
Kind Pharmaceuticals LLC
Recruiting
Last update posted :
02/29/2024
Initiation :
10/05/2022
Primary completion :
05/01/2026
Completion :
05/01/2026
HER-2 • ER
|
HER-2 negative
|
AND019
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login